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dentification
of
cell
signaling
mechanisms mediating seizure-related
neuronal death and epileptogenesis is
important for developing more effective
therapies for epilepsy. The mammalian
target of rapamycin (mTOR) pathway
has recently been implicated in regulating neuronal death and epileptogenesis
in rodent models of epilepsy. In particular, kainate-induced status epilepticus causes abnormal activation of the
mTOR pathway, and the mTOR inhibitor, rapamycin, can decrease the development of neuronal death and chronic
seizures in the kainate model. Here, we
discuss the significance of these findings
and extend them further by identifying
upstream signaling pathways through
which kainate status epilepticus activates
the mTOR pathway and by demonstrating limited situations where rapamycin
may paradoxically increase mTOR activation and worsen neuronal death in the
kainate model. Thus, the regulation of
seizure-induced neuronal death and epileptogenesis by mTOR is complex and
may have dual, opposing effects depending on the physiological and pathological context. Overall, these findings have
important implications for designing
potential neuroprotective and antiepileptogenic therapies that modulate the
mTOR pathway.
Introduction
Epilepsy is one of the most common
neurological disorders, affecting approximately 1% of people, and is characterized
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by significant morbidity and mortality.
Although there are a variety of underlying causes for epilepsy, seizures themselves
are often implicated in causing progressive epileptogenesis and neuronal death,
contributing to medically-intractable epilepsy and co-morbid cognitive deficits.
Currently available medications simply
suppress seizure symptomatically, but do
not appear to prevent seizure-induced
brain injury or reverse the underlying
mechanisms of epileptogenesis.1 Thus, it
is now widely recognized that novel therapies for epilepsy need to be developed that
have neuroprotective, antiepileptogenic or
disease-modifying properties.2-4
In order to develop disease-modifying
therapies for epilepsy, a better understanding of the cellular and molecular mechanisms of epileptogenesis and
seizure-induced brain injury is required.
While traditionally seizure medications
have targeted ion channels and neurotransmitters receptors that directly contribute
to neuronal excitability, a recent trend
has been to identify and target primary
cell signaling pathways that initially trigger downstream mechanisms mediating
neuronal injury and epileptogenesis. The
mammalian target of rapamycin (mTOR)
signaling pathway represents a rational candidate, because mTOR regulates
numerous cellular functions and mechanisms that affect cell survival and death,
neuronal excitability and epileptogenesis.5
Furthermore, available drugs exist that
specifically inhibit mTOR and could be
readily tested as neuroprotective and antiepileptogenic therapies for epilepsy.
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Figure 1. Regulation and effectors of the mTOR signaling pathway. In response to environmental
or physiological stimuli, upstream pathways, primarily involving cascades of protein kinases,
may either activate (PI3K/Akt) or inhibit (AMPK) mTOR via modulation of the tuberin-hamartin
complex and Rheb GTPase (not shown). In turn, mTOR controls multiple downstream pathways/
effectors that individually modulate cell growth and protein synthesis, cell cycle and proliferation,
and cell death/apoptosis. Abbreviations: 4EBP1, elongation factor 4E binding protein 1; AMPK,
AMP-activated protein kinase; eIF4E, elongation initiation factor 4E; mTOR, mammalian target of
rapamycin; PI3K, phosphatidylinositide-3 kinase.

mTOR: A Central Regulator
of Protein Synthesis, Cell Growth
and Cell Death
mTOR is a serine-threonine protein kinase
that is highly conserved among species and
is implicated in a number of basic cellular functions, broadly related to growth,
proliferation, survival, homeostasis and
death.6-9 Under physiological conditions of
cellular growth and anabolism, the mTOR
pathway becomes activated and promotes
protein synthesis, increased cell size, and
cellular proliferation, whereas during states
of metabolic stress or catabolism, mTOR
activity may be inhibited, thus limiting
these cellular processes. mTOR has also
been implicated in regulating neuronal
death, in particular apoptosis, although
this relationship is complicated, with
mTOR having both pro-apoptotic and
anti-apoptotic actions depending on the
physiological or pathological conditions.
A number of upstream signaling
pathways can modulate mTOR activity in
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response to environmental stimuli or intracellular signals, including nutrient and
energy status, growth factors and stress
(Fig. 1). Thus, during anabolic states in
the presence of nutrients, growth factors
or insulin, specific upstream regulators,
such as the phosphatidylinositol-3 kinase
(PI3K)/Akt (protein kinase B) pathway,
stimulate mTOR, leading to increased protein synthesis, cellular growth and proliferation.10,11 In catabolic states with energy
or oxygen deprivation, other upstream
pathways, such as AMP-kinase (AMPK),
inhibit mTOR activity, thus limiting protein translation and cellular growth, proliferation and metabolism.12,13 Activation
or inhibition of mTOR by upstream pathways is generally accomplished through
opposing effects on the tuberous sclerosis
gene products, hamartin and tuberin, and
the small GTPase protein, Rheb.
Downstream from mTOR, there are
multiple signaling pathways that mediate
the various functional effects of mTOR
(Fig. 1). The anabolic actions of mTOR on

cell growth are primarily accomplished by
stimulation of protein synthesis. mTOR
triggers activity of ribosomal S6 kinase-1
(S6K1), which phosphorylates the ribosomal protein S6, promoting ribosomal
biogenesis and protein translation.14-16 In
addition, mTOR induces an inhibition
of the elongation factor 4E binding protein 1 (4EBP1) and subsequent activation
(release of inhibition) of the mRNA elongation initiation factor 4E (eIF4E), also
triggering protein synthesis.15,16 Parallel
to regulation of the S6K/S6 and 4EBP1/
eIF4E pathways in stimulating protein
synthesis and cell growth, other signaling elements downstream from mTOR,
such as p27/cyclin-dependent kinases,
are responsible for mediating mTOR
regulation of cell cycle progression and
proliferation.17-19 Furthermore, mTOR
may directly modulate separate mechanisms controlling neuronal death, such
as the pro-apoptotic molecules, BAD and
Bcl-2.20,21 Overall, the mTOR signaling
pathway is in a central position to serve as
a master regulator of multiple, interrelated
functions and mechanisms relevant to cell
growth, proliferation and death.
mTOR: A Central Regulator
of Seizure-Related Neuronal Death
and Epileptogenesis
The mTOR pathway has emerged as a
leading candidate for a signaling mechanism that could be involved in seizurerelated neuronal death and epileptogenesis
in several types of epilepsy.5 In mouse
models of the genetic epilepsy, Tuberous
Sclerosis Complex, excessive activity of
the mTOR pathway due to inactivation of the upstream regulators, TSC1 or
TSC2, promotes epileptogenesis, neuronal hypertrophy and glial proliferation,
and the mTOR inhibitor, rapamycin,
prevents the development of epilepsy and
the underlying cellular and histological
brain abnormalities in these mice.22,23
Rapamycin also reverses similar histological and behavioral abnormalities in related
genetic models with abnormal mTOR
signaling due to upstream PTEN gene
inactivation.24-26 By analogy, given the
central role of mTOR in multiple cellular
functions relevant to neuronal survival
and excitability, the mTOR pathway has
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also been implicated in mediating neuronal death and epileptogenesis in rodent
models of acquired epilepsy due to brain
injury. The mTOR pathway is activated in
animal models of traumatic brain injury
(TBI) and rapamycin has neuroprotective
effects against neuronal death and functional deficits following TBI, although
effects on posttraumatic epilepsy have not
been described.27,28 mTOR is also triggered in the pilocarpine model of acquired
epilepsy and mediates axonal sprouting, a
putative mechanism of epileptogenesis.29
In a recent study, we have reported that
the mTOR pathway is involved in neuronal death and epileptogenesis in the
related kainate model of limbic epilepsy
in rats.30 In the kainate model, an initial
episode of prolonged seizures (status epilepticus), induced by administration of
the glutamate agonist, kainate, triggers
neuronal death and other cellular and
molecular changes that promote epileptogenesis. After recovery from the status
epilepticus and following a latent period
of days to weeks, these changes lead to the
development of spontaneous seizures. In
this model, we showed that kainate causes
activation of the mTOR pathway both
acutely during status epilepticus and more
chronically for several weeks coinciding
with the latent period of epileptogenesis.30
The mTOR inhibitor rapamycin prevents
the abnormal kainate-induced mTOR
activation and, depending on the timing
of the rapamycin administration, causes
a variable decrease in putative cellular
mechanisms of epileptogenesis, including hippocampal neuronal death, neurogenesis and axonal sprouting. Rapamycin
also causes a corresponding decrease in the
development of spontaneous seizures.30
Thus, these studies suggested that mTOR
plays a critical role in activating multiple
downstream mechanisms of neuronal
injury and epileptogenesis in the kainate
model and that rapamycin has neuroprotective and antiepileptogenic actions in
this model.
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Figure 2. Kainate status epilepticus activates Akt, an upstream regulator of the mTOR pathway.
Western blots of hippocampal homogenates were performed at various time points following
kainate status epilepticus in adult rats. Compared to control rats, the ratio of P-Akt to total Akt was
increased acutely with kainate status epilepticus and remained elevated for several weeks.
*p < 0.05, **p < 0.01 by ANOVA, compared to the control group.

Figure 3. Rapamycin causes paradoxical exacerbation of kainate-induced mTOR activation when
administered within one hour of kainate. Adult rats were injected with vehicle (Con), kainate
(15 mg/kg, i.p.), or rapamycin (6 mg/kg) at different intervals before or after kainate. Kainate
alone (KA) causes increased mTOR activation, as reflected by the ratio of phospho-S6 to total S6
expression measured 7 days after kainate injection, compared to vehicle (Con). Pretreatment with
rapamycin one day prior to kainate inhibits the kainate-induced mTOR activation (Pre-1d). In contrast, rapamycin administered within one hour before (Pre-1 h) or after (Post-1 h) kainate causes a
paradoxical increase in the kainate-induced mTOR activation. *p < 0.05, ***p < 0.001 by ANOVA,
compared to the KA group.
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Paradoxical Activation of the
mTOR Pathway and Exacerbation
of Neuronal Death by Rapamycin
in the Kainate Model

Figure 4. Rapamycin causes paradoxical exacerbation of kainate-induced cell death when administered within one hour of kainate. Kainate status epilepticus causes cell death in the CA1 region
of hippocampus, as detected by Fluoro-Jade B (FJB) staining 7 days after status epilepticus. Pretreatment with rapamycin one day prior to kainate inhibits the kainate-induced neuronal death
(Pre-1d). In contrast, rapamycin administered within one hour before (Pre-1 h) or after (Post-1 h)
kainate causes a paradoxical increase in the kainate-induced cell death. *p < 0.05, ***p < 0.001 by
ANOVA, compared to the KA group.

Upstream Activation of the mTOR
Pathway by Kainate-Induced
Status Epilepticus
The specific mechanisms involved in
mTOR pathway regulation of seizurerelated neuronal death and epileptogenesis deserve further attention. In particular,
the upstream signaling pathways that
trigger mTOR activation in the kainate
model are not known. Given that kainate is a glutamate agonist and that large
amounts of endogenous glutamate are
released during status epilepticus, a rational hypothesis is that stimulation of the
Akt/PI3K pathway by glutamate31,32 and
calcium influx during kainate status epilepticus causes the downstream activation
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of the mTOR pathway (Fig. 1). Other
recent studies from our lab support that
Akt is activated by kainate status epilepticus acutely and more chronically over a
couple of weeks, correlating with mTOR
pathway activation that occurs during the
latent period of epileptogenesis (Fig. 2).
In contrast, no acute alterations in activation of the AMPK signaling pathway, also
upstream from mTOR, were observed
with kainate (data not shown). In addition to further defining the cell signaling mechanisms involved, these findings
provide potential additional strategies
for preventing seizure-induced neuronal
death and epileptogenesis, as the Akt/
PI3K could be targeted with specific PI3K
inhibitors.

The number and complexity of upstream
and downstream signaling pathways and
mechanisms that may regulate and mediate the effects of mTOR, as well as multiple positive and negative feedback steps
that occur among these pathways, suggest
that the mTOR pathway may have complicated, potentially dual effects on some
cellular functions. For example, depending on the physiological or pathological
conditions, mTOR activation has been
demonstrated to have both pro-apoptotic
and anti-apoptic effects.20,21 In pilot studies to determine effective dosing regimens
of rapamycin for inhibiting the kainateinduced mTOR activation,30 we initially
observed a paradoxical exacerbation of
the increased mTOR pathway activity, as
reflected by downstream P-S6 expression,
when rapamycin and kainate were administered within a short time period of each
other. Thus, in our published studies, we
only injected rapamycin at least twentyfour hours before (pretreatment) or after
(posttreatment) kainate in order to obtain
the expected inhibition of mTOR activity.30 Further analysis of the initial paradoxical phenomenon has confirmed that
rapamycin administered within one hour
of kainate injection causes a higher level
of mTOR activation than kainate in the
absence of rapamycin (Fig. 3). If rapamycin is injected at greater intervals from the
kainate, the expected inhibition of mTOR
activation is again observed. The paradoxical mTOR activation by rapamycin
is associated with greater neuronal death
several days after kainate status epilepticus (Fig. 4). Thus, under limited circumstances, it appears that rapamycin causes
a paradoxical activation of the mTOR
pathway, and depending on the situation,
rapamycin has the potential to have either
neuroprotective or exacerbating effects on
cell death.
The specific molecular mechanisms
leading to this paradoxical activation of
the mTOR pathway by rapamycin in the
kainate model are unknown. A speculative
explanation is that during periods of especially high mTOR activity, such as during
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the acute phase of kainate-induced seizure
activity, mTOR inhibition by rapamycin
may allow alternative feed forward pathways for stimulating downstream mTOR
effectors, such as P-S6, to be activated
and overcompensate for direct mTOR
inhibition. Future studies are needed to
define these mechanisms. Irregardless of
the specific mechanisms, these findings
highlight the complexity of the involvement of the mTOR pathway in responding
to upstream stimuli and in turn, regulating downstream effectors. The mTOR
pathway may have opposing effects on
mechanisms of neuronal death and epileptogenesis, depending on the situation.
This has direct clinical implications for
the use of mTOR inhibitors as potential
neuroprotective and antiepileptogenic
agents, as there could be circumstances in
which such treatment could worsen neurological status.
Conclusions
mTOR is a central signaling pathway that
regulates a number of important cellular
functions and mechanisms involved in seizure-related cell death and epileptogenesis.
Work in animal models of both genetic and
acquired epilepsies suggests that modulators of the mTOR pathway may have beneficial neuroprotective and antiepileptogenic
effects. However, paradoxical effects of
mTOR inhibition have also been observed
and suggest that mTOR may serve as a
master switch that can trigger opposing
actions on neuronal death and epileptogenesis under different conditions. This dual
role of mTOR needs to be considered in
designing potential therapies for epilepsy
that modulate the mTOR pathway.
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